×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BMRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/24
06:18 am
bmrn
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks [Yahoo! Finance]
Low
Report
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks [Yahoo! Finance]
3/21
08:09 pm
bmrn
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock [Yahoo! Finance]
Low
Report
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock [Yahoo! Finance]
3/21
05:58 pm
bmrn
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Low
Report
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
3/21
06:46 am
bmrn
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) [Yahoo! Finance]
Low
Report
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) [Yahoo! Finance]
3/20
10:02 am
bmrn
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks [Yahoo! Finance]
Low
Report
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks [Yahoo! Finance]
3/20
09:28 am
bmrn
The Exceptional Women Alliance Announces Selection of Dr. Roslyn F. Schneider [Yahoo! Finance]
Low
Report
The Exceptional Women Alliance Announces Selection of Dr. Roslyn F. Schneider [Yahoo! Finance]
3/20
09:00 am
bmrn
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clini
Low
Report
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clini
3/18
02:07 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
2/19/2025
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
Report
5.3%
biomarin pharmaceutical inc.
2/19/2025
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
Report
5.3%
biomarin pharmaceutical inc.
2/19/2025
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
Report
5.3%
biomarin pharmaceutical inc.
2/19/2025
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
Report
5.3%
biomarin pharmaceutical inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/20
07:39 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 19 Filed by: Burkhart Erin
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 19 Filed by: Burkhart Erin
3/19
09:36 am
bmrn
Form 144 BIOMARIN PHARMACEUTICAL Filed by: Burkhart Erin
Low
Report
Form 144 BIOMARIN PHARMACEUTICAL Filed by: Burkhart Erin
3/18
07:53 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 14 Filed by: Burkhart Erin
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 14 Filed by: Burkhart Erin
3/18
07:51 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 14 Filed by: Davis George Eric
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 14 Filed by: Davis George Eric
3/18
06:26 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Hubbard Cristin
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Hubbard Cristin
3/18
06:23 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Friberg Gregory R
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Friberg Gregory R
3/18
06:22 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 14 Filed by: Guyer Charles Greg
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 14 Filed by: Guyer Charles Greg
3/18
06:19 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 14 Filed by: Mueller Brian
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 14 Filed by: Mueller Brian
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/14
Form 4 BIOMARIN PHARMACEUTICAL For: May 10 Filed by: BIENAIME JEAN JACQUES
7.5%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
TOP News Decliners
3/11
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 03 Filed by: BIENAIME JEAN JACQUES
-12.3%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: